Multicentre trial of a programmable implantable insulin pump in type I diabetes

M. Pinget, N. Jeandidier, F. Ortega, D. Wix, J. Margetaux, C. Feinbock, J. Diglas, H. Mendl, K. Irsigler, M. Scavini, G. Petrella, M. Torri, M. Cristallo, G. Pozza, H. J. Luddeke, T. Groth, R. Renner, K. D. Hepp, J. L. Selam

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Programmable implantable pumps permitting variable-rate intraperitoneal insulin infusion are currently investigated as a potential alternative to subcutaneous insulin therapy. An improved version of the Siemens implantable system has been evaluated in 6 European centres on 31 type I diabetic patients treated for 10-30 months. Contrary to other pump models there were no proven pump malfunctions and only one no-flow reduction unrelated to catheter obstruction. The latter resulted in 12 surgical catheter replacements. There were 2.0 incidents of programmer malfunctions per patient-year easily managed by reconfiguration or replacement. Insulin remained clear and active in the pump reservoir and glycaemic control remained in the near-normoglycaemic range. Thus, insulin therapy with the Siemens implantable pump is feasible and effective up to 2.5 years.

Original languageEnglish
Pages (from-to)322-325
Number of pages4
JournalInternational Journal of Artificial Organs
Volume18
Issue number6
Publication statusPublished - 1995

Fingerprint

Insulin Infusion Systems
Insulin
Medical problems
Type 1 Diabetes Mellitus
Multicenter Studies
Pumps
Catheters
Catheter Obstruction
Parenteral Infusions
Therapeutics

Keywords

  • implantable devices
  • intensive insulin therapy
  • intraperitoneal insulin delivery

ASJC Scopus subject areas

  • Biophysics

Cite this

Pinget, M., Jeandidier, N., Ortega, F., Wix, D., Margetaux, J., Feinbock, C., ... Selam, J. L. (1995). Multicentre trial of a programmable implantable insulin pump in type I diabetes. International Journal of Artificial Organs, 18(6), 322-325.

Multicentre trial of a programmable implantable insulin pump in type I diabetes. / Pinget, M.; Jeandidier, N.; Ortega, F.; Wix, D.; Margetaux, J.; Feinbock, C.; Diglas, J.; Mendl, H.; Irsigler, K.; Scavini, M.; Petrella, G.; Torri, M.; Cristallo, M.; Pozza, G.; Luddeke, H. J.; Groth, T.; Renner, R.; Hepp, K. D.; Selam, J. L.

In: International Journal of Artificial Organs, Vol. 18, No. 6, 1995, p. 322-325.

Research output: Contribution to journalArticle

Pinget, M, Jeandidier, N, Ortega, F, Wix, D, Margetaux, J, Feinbock, C, Diglas, J, Mendl, H, Irsigler, K, Scavini, M, Petrella, G, Torri, M, Cristallo, M, Pozza, G, Luddeke, HJ, Groth, T, Renner, R, Hepp, KD & Selam, JL 1995, 'Multicentre trial of a programmable implantable insulin pump in type I diabetes', International Journal of Artificial Organs, vol. 18, no. 6, pp. 322-325.
Pinget M, Jeandidier N, Ortega F, Wix D, Margetaux J, Feinbock C et al. Multicentre trial of a programmable implantable insulin pump in type I diabetes. International Journal of Artificial Organs. 1995;18(6):322-325.
Pinget, M. ; Jeandidier, N. ; Ortega, F. ; Wix, D. ; Margetaux, J. ; Feinbock, C. ; Diglas, J. ; Mendl, H. ; Irsigler, K. ; Scavini, M. ; Petrella, G. ; Torri, M. ; Cristallo, M. ; Pozza, G. ; Luddeke, H. J. ; Groth, T. ; Renner, R. ; Hepp, K. D. ; Selam, J. L. / Multicentre trial of a programmable implantable insulin pump in type I diabetes. In: International Journal of Artificial Organs. 1995 ; Vol. 18, No. 6. pp. 322-325.
@article{f1448ffb581e4ec3902ba7c126cb68c9,
title = "Multicentre trial of a programmable implantable insulin pump in type I diabetes",
abstract = "Programmable implantable pumps permitting variable-rate intraperitoneal insulin infusion are currently investigated as a potential alternative to subcutaneous insulin therapy. An improved version of the Siemens implantable system has been evaluated in 6 European centres on 31 type I diabetic patients treated for 10-30 months. Contrary to other pump models there were no proven pump malfunctions and only one no-flow reduction unrelated to catheter obstruction. The latter resulted in 12 surgical catheter replacements. There were 2.0 incidents of programmer malfunctions per patient-year easily managed by reconfiguration or replacement. Insulin remained clear and active in the pump reservoir and glycaemic control remained in the near-normoglycaemic range. Thus, insulin therapy with the Siemens implantable pump is feasible and effective up to 2.5 years.",
keywords = "implantable devices, intensive insulin therapy, intraperitoneal insulin delivery",
author = "M. Pinget and N. Jeandidier and F. Ortega and D. Wix and J. Margetaux and C. Feinbock and J. Diglas and H. Mendl and K. Irsigler and M. Scavini and G. Petrella and M. Torri and M. Cristallo and G. Pozza and Luddeke, {H. J.} and T. Groth and R. Renner and Hepp, {K. D.} and Selam, {J. L.}",
year = "1995",
language = "English",
volume = "18",
pages = "322--325",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "6",

}

TY - JOUR

T1 - Multicentre trial of a programmable implantable insulin pump in type I diabetes

AU - Pinget, M.

AU - Jeandidier, N.

AU - Ortega, F.

AU - Wix, D.

AU - Margetaux, J.

AU - Feinbock, C.

AU - Diglas, J.

AU - Mendl, H.

AU - Irsigler, K.

AU - Scavini, M.

AU - Petrella, G.

AU - Torri, M.

AU - Cristallo, M.

AU - Pozza, G.

AU - Luddeke, H. J.

AU - Groth, T.

AU - Renner, R.

AU - Hepp, K. D.

AU - Selam, J. L.

PY - 1995

Y1 - 1995

N2 - Programmable implantable pumps permitting variable-rate intraperitoneal insulin infusion are currently investigated as a potential alternative to subcutaneous insulin therapy. An improved version of the Siemens implantable system has been evaluated in 6 European centres on 31 type I diabetic patients treated for 10-30 months. Contrary to other pump models there were no proven pump malfunctions and only one no-flow reduction unrelated to catheter obstruction. The latter resulted in 12 surgical catheter replacements. There were 2.0 incidents of programmer malfunctions per patient-year easily managed by reconfiguration or replacement. Insulin remained clear and active in the pump reservoir and glycaemic control remained in the near-normoglycaemic range. Thus, insulin therapy with the Siemens implantable pump is feasible and effective up to 2.5 years.

AB - Programmable implantable pumps permitting variable-rate intraperitoneal insulin infusion are currently investigated as a potential alternative to subcutaneous insulin therapy. An improved version of the Siemens implantable system has been evaluated in 6 European centres on 31 type I diabetic patients treated for 10-30 months. Contrary to other pump models there were no proven pump malfunctions and only one no-flow reduction unrelated to catheter obstruction. The latter resulted in 12 surgical catheter replacements. There were 2.0 incidents of programmer malfunctions per patient-year easily managed by reconfiguration or replacement. Insulin remained clear and active in the pump reservoir and glycaemic control remained in the near-normoglycaemic range. Thus, insulin therapy with the Siemens implantable pump is feasible and effective up to 2.5 years.

KW - implantable devices

KW - intensive insulin therapy

KW - intraperitoneal insulin delivery

UR - http://www.scopus.com/inward/record.url?scp=0029125317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029125317&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 322

EP - 325

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

IS - 6

ER -